Shan Guleria
Papers
1
Total Citations
24
H-Index
1
About
Shan Guleria is a leading figure in radiation oncology, with a focused expertise in stereotactic body radiation therapy (SBRT) for prostate cancer. His work is distinguished by a meticulous approach to minimizing treatment toxicity, particularly acute urinary morbidity. In his highly cited 2016 study, Guleria pioneered a dual strategy to protect patients: prophylactic alpha-adrenergic antagonists to manage urinary symptoms and deliberate urethral dose reduction to spare the delicate prostatic urethra from high radiation fractions. This research, which has garnered 24 citations, provided critical evidence that SBRT could be delivered safely without compromising its potent anti-cancer effect. By systematically addressing the primary barrier to patient acceptance—fear of urinary side effects—Guleria’s contributions have helped solidify SBRT as a standard, patient-friendly option. His work continues to influence clinical protocols, demonstrating that technical precision in radiation planning, combined with thoughtful medical management, can dramatically improve quality of life for men undergoing this advanced treatment.
Research Focus
Key Achievements
Top Papers
- 1